Print this page
breast
-
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.
Protocol: 042211Principal Investigator:
-
Coral Omene
Applicable Disease Sites: Breast -
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-Stage Triple-Negative Breast Cancer.
Protocol: 042304Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE).
Protocol: 042305Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
RADIANT Study: Phase Ib Study of Pre-op Radiation with Abemaciclib and Letrozole in Early Stage Breast Cancer.
Protocol: 042311Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
An Adjuvant Endocrine-Based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer.
Protocol: 042312Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score less than or equal to 25 (OFSET).
Protocol: 042313Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.
Protocol: 042315Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A First-in-Human Study of Mutant-Selective PI3K Alpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer.
Protocol: 042402Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
Feasibility Study of Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer.
Protocol: 042403Principal Investigator:
-
Coral Omene
Applicable Disease Sites: Breast -
Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease.
Protocol: 042404Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy.
Protocol: 042405Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A Phase 3, Randomized, Open-Label, Controlled Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination with Physician's Choice Chemotherapy, for the Treatment of Participants with Metastatic HER2-Positive Breast Cancer.
Protocol: 042406Principal Investigator:
-
Coral Omene
Applicable Disease Sites: Breast -
A Phase 2, Open-Label Study of PCS6422 with Capecitabine in Patients with Advanced or Metastatic Breast Cancer.
Protocol: 042407Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer
Protocol: 042408Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Protocol: 042410Principal Investigator:
-
Coral Omene
Applicable Disease Sites: Breast -
A Multicenter, Open Label, Phase III Extension Trial to Study the Long-Term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Protocol: 051804Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Any Site